Services

Platform 1 Biomolecules production

• U1-S01.
• U1-S02.
• U1-S03.
• U1-S04.
• U1-S05.
• U1-S06.
• U2-S01. Scientific and technical support (Remote)
• U2-S02. Hapten synthesis (Remote) OUTSTANDING
• U2-S03. Preparation of Bioconjugates and Molecular Probes (Remote) OUTSTANDING
• U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING
• U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING
• U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING
• U2-S07. Antibody purification (Remote) OUTSTANDING
• U2-S08. Inmunochemical methods development (Remote) OUTSTANDING
• U28-S07.
• U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING
• U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
• U29-S03. Special nucleotides for oligonucleotide synthesis. (Remote) OUTSTANDING
• U3-S01.
• U3-S02.
• U3-S03.
• U3-S04. Peptide libraries (Remote) OUTSTANDING

Platform 2 Biomaterials & nanomaterials production

• U6-S01. Use of High-pressure laboratory-scale plant
• U6-S02. High-pressure phase analysis – solubility, emulsification (Remote) OUTSTANDING
• U6-S03
• U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
• U6-S05
• U6-S06.
• U6-S07.
• U6-S08.
• U6-S09.
• U6-S11. Specific density of powders (On-site&Remote) OUTSTANDING
• U6-S12. Packed (tapped) density (On-site) OUTSTANDING
• U6-S14. Quantitative studies of biomolecular interactions by calorimetric measurements (On-site) OUTSTANDING
• U7-S01.
• U7-S03.
• U7-S04.
• U7-S07.
• U7-S08.
• U7-S09.
• U7-S10.
• U7-S11.
• U8-S01.
• U8-S02.
• U8-S04.
• U8-S05.
• U8-S06.
• U9-S01.
• U9-S02.
• U9-S03.
• U9-S04.
• U9-S05.
• U9-S6.

• U10-S01.
• U10-S02.
• U10-S03.
• U10-S04.
• U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING
• U10-S09. Characterization and development of pulmonar formulations (On-site&Remote) OUTSTANDING

Platform 3 Preclinical validation Tissue, Biomaterials and Surfaces Characterization

• U12-S01.
• U12-S02.
• U12-S03.
• U12-S04.
• U12-S05.
• U12-S06.
• U12-S07.
• U12-S08.
• U13-S01.
• U13-S03.
• U13-S04.
• U13-S05.
• U13-S06.
• U13-S08.
• U13-S09.
• U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING
• U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING
• U14-S03. Biomecanic evaluation of plantar pressure in large animal models (On-site) OUTSTANDING
• U14-S04. Cytokine quantification assays (On-site&Remote) OUTSTANDING
• U14-S05. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING
• U14-S06. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING
• U15-S01. Magnetometry (Remote) OUTSTANDING
• U15-S02. Relaxometry (Remote) OUTSTANDING
• U16-S01. XPS (Remote) OUTSTANDING
• U16-S02. Ellipsometry (Remote) OUTSTANDING
• U16-S03. Calorimetry (Remote) OUTSTANDING
• U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING
• U16-S05. Characterization service by contact angle goniometry OUTSTANDING
• U16-S06. Topographic characterization service using optical profilometry OUTSTANDING
• U16-S07. Evaluation of the adhesion capacities and formation of biolayers of microorganisms on materials. Evaluation of bactericidal and/or bacteriostatic responses of materials. OUTSTANDING
• U17-S01.
• U18-S01.
• U18-S02.
• U19-S01.
• U19-S03.
• U30-S01.
• U30-S02.
• U30-S03.
• U30-S04.
• U30-S05.
• U30-S06.
• U30-S07.
• U30-S08.
• U30-S09.

Platform 4 Preclinical validation bioimaging

• U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING
• U20-S010. Ultrasound imaging in vivo (Remote) OUTSTANDING
• U20-S012. Inmunihistochemistry on histological samples (Remote) OUTSTANDING
• U20-S013. Detection of microbial (bacterial and mycoplasma) contaminationpre
• U20-S014. Hemocompatibility: hemolysis, platelet aggregation, plasma coagulation times and complement activation
• U20-S015. Cytotoxicity: proliferation, LDH, apoptosis and ROS
• U20-S02. Animal models in oncology (Remote) OUTSTANDING
• U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING
• U20-S04. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
• U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING
• U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING
• U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING
• U20-S08. Immunotoxicity assays (On-site&Remote) OUTSTANDING
• U20-S09. X-ray imaging in vitro and in vivo (Remote) OUTSTANDING
• U20-S11. Histological porcessing, section and staining (Remote) OUTSTANDING
• U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
• U22-S01. Animal Housing (Remote) OUTSTANDING
• U22-S02. In vivo experimental design/consultancy for preclinal studies (On-site&Remote)
• U22-S03. In vivo toxicology in rodent and non-rodent species (On-site)
• U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site)
• U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site)
• U22-S06. In vivo safety and effcacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING
• U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING
• U22-S08. Dosing of test substances and non clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING
• U23-S01. In vitro fertilisation studies and embryo culture media viability (Onsite&Remote) OUTSTANDING
• U23-S02. Embryo culture media viability studies (Onsite&Remote) OUTSTANDING
• U23-S03. Micromanipulation and microinjection (Onsite&Remote) OUTSTANDING
• U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site&Remote) OUTSTANDING
• U23-S05. In vitro Maduration (On-site&Remote) OUTSTANDING
• U23-S06. IMSI system (On-site&Remote) OUTSTANDING
• U23-S07. Laser System and Biopsed of blastomeres (On-site&Remote) OUTSTANDING
• U23-S08. Oosight system (On-site&Remote) OUTSTANDING
• U23-S09. Quality control for Human Assisted Reproduction clinics (On-site&Remote) OUTSTANDING
• U24-S01 Evaluation of therapies for cardiovascular disease
• U24-S02. Medical Imaging for Minimally Invasive Surgery (Onsite&Remote) OUTSTANDING
• U25-S03.
• U25-S05.
• U25-S06.
• U25-S07.
• U25-S08.
• U25-S09.
• U26-S01.
• U26-S02.
• U26-S03.
• U26-S04.
• U26-S05.
• U26-S06.
• U28-S01.
• U28-S010.
• U28-S011.
• U28-S012. Cryo-ultramicrotomy (Onsite&Remote) OUTSTANDING
• U28-S013. High-pressure freezing (Onsite&Remote) OUTSTANDING
• U28-S014. Freeze substitution (Onsite&Remote) OUTSTANDING
• U28-S015. Sample vitrification (Onsite&Remote) OUTSTANDING
• U28-S016.
• U28-S017.
• U28-S018.
• U28-S019.
• U28-S02.
• U28-S020.
• U28-S021. Nuclear Molecular Imaging (PET/SPECT/CT)(Onsite&Remote)
• U28-S03.
• U28-S04.
• U28-S05.
• U28-S06.
• U28-S08.

Platform 5 High perfomance computing

• U27-S01. Remote access to HPC (On-site&Remote)
• U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING
• U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
• U27-S04. Modeling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING
• U27-S05. Massive parallel processing (Onsite&Remote)
• U27-S06. Mass storage (Onsite&Remote)